Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $103M | $113M | $106M | $115M | $130M | $148M | $114M | $121M | $120M | $113M |
| Revenue growth | — | 9.7% | -6.9% | 8.6% | 13.8% | 13.3% | -23.0% | 6.1% | -0.7% | -5.9% |
| Gross profit | — | — | $74.3M | $85.9M | $69.0M | $82.9M | $73.2M | $82.5M | $76.0M | $63.8M |
| Gross margin | — | — | 70.4% | 74.9% | 52.9% | 56.1% | 64.3% | 68.3% | 63.4% | 56.6% |
| Operating income | $50.6M | $45.7M | $21.7M | $34.2M | -$28.3M | $2.62M | $3.67M | $844K | -$5.10M | -$11.1M |
| Operating margin | 49.0% | 40.3% | 20.6% | 29.9% | -21.7% | 1.8% | 3.2% | 0.7% | -4.3% | -9.8% |
| Net income | $32.5M | $31.8M | $18.7M | $27.2M | -$24.0M | $4.13M | -$14.9M | -$82.7M | -$56.4M | -$10.9M |
| Net margin | 31.5% | 28.1% | 17.7% | 23.7% | -18.4% | 2.8% | -13.1% | -68.4% | -47.0% | -9.6% |
| EPS (diluted) | $2.15 | $2.11 | $1.27 | $1.89 | -$1.69 | $0.28 | -$1.02 | -$5.64 | -$3.83 | -$0.76 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $24.4M | $40.8M | $34.9M | $37.0M | $13.1M | $8.40M | $4.41M | -$1.79M | $5.40M | $11.2M |
| Capital expenditures | $14.0M | $8.98M | $4.66M | $2.83M | $1.63M | $5.14M | $7.49M | $5.43M | $7.73M | $6.83M |
| Free cash flow | $10.4M | $31.8M | $30.3M | $34.2M | $11.4M | $3.25M | -$3.08M | -$7.21M | -$2.33M | $4.36M |
| Share buybacks | $25.0M | — | $30.0M | $30.0M | $0.00 | $0.00 | $0.00 | $5.00M | $10.9M | $9.48M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $104M | $133M | $89.0M | $157M | $95.8M | $94.4M | $86.3M | $68.7M | $55.6M | $57.5M |
| Total assets | $240M | $283M | $279M | $331M | $366M | $348M | $349M | $271M | $203M | $190M |
| Shareholders' equity | $223M | $263M | $264M | $288M | $272M | $287M | $286M | $212M | $154M | $143M |
| Retained earnings | $168M | $200M | $218M | $245M | $221M | $226M | $211M | $128M | $71.7M | $60.8M |
| Shares (wtd avg diluted) | 15.1M | 15.1M | 14.7M | 14.4M | 14.2M | 14.6M | 14.8M | 14.7M | 14.7M | 14.3M |
Every figure is extracted from Anika Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.